Vivos Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $22.4M
- Price
- $0.0453
- % Change (Daily % change from the live per-ticker quote feed.)
- +5.01%
- Volume
- 1.5M
About
Vivos Inc. is a medical technology company focused on radiation oncology, specializing in the development of internal radiation therapy devices for managing tumors that cannot be surgically removed. Their offerings include RadioGel, an injectable particle-gel that utilizes yttrium-90 for targeted radiation treatment of cancerous growths in both humans and animals. Additionally, the company provides IsoPet, a specific treatment for solid tumors found in animals. Established in 1994, Vivos Inc. is based in Richland, Washington. It previously operated under the name Advanced Medical Isotope Corporation before rebranding to Vivos Inc. in December 2017.
Quick stats
Shares outstanding494.2M
Computed float467.1M
Float / shares94.5%
Cash runway (months)9.4
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001449349
Websitehttps://www.radiogel.com
AI Summary
AI-generated1/23
minorbullishoperations update
Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology
Vivos Inc. announced the peer-reviewed publication of a paper characterizing its PrecisionGel thermogel polymer platform in Elsevier's Journal of Drug Delivery Science and Technology.
The paper summarizes three years of development research at Akina Inc., which developed and produces the PrecisionGel polymer used as the carrier component of both IsoPet and RadioGel; the polymer is also marketed independently as a universal drug-delivery carrier.
Management says the publication strengthens clinical-program credibility at Mayo Clinic and Health Care Global Cancer Centre in India and supports future regulatory submissions in the UK, Australia, EU, Japan and India, while bolstering licensing discussions with pharmaceutical companies.
No new clinical, regulatory, or financial data was disclosed, making this a credibility milestone rather than a near-term catalyst for the pre-commercial micro-cap.
Red flags
- Promotional announcement with no new clinical, regulatory, or financial data
- Strategic benefits cited (licensing deals, regulatory acceptances) remain prospective and unconfirmed